Table 2.
Univariate and multivariate Cox regression analyses for treatment outcomes.
| Variables | Local recurrence-free survival |
Locoregional recurrence-free survival |
Distant metastasis-free survival |
Progression-free survival |
Cancer-specific survival |
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate |
Multivariate |
Univariate |
Multivariate |
Univariate |
Multivariate |
Univariate |
Multivariate |
Univariate |
Multivariate |
|||||||||||
| P value |
HR (95 % CI) |
P value |
HR (95 % CI) |
P value |
HR (95 % CI) |
P value |
HR (95 % CI) |
P value |
HR (95 % CI) |
P value |
HR (95 % CI) |
P value |
HR (95 % CI) |
P value |
HR (95 % CI) |
P value |
HR (95 % CI) |
P value |
HR (95 % CI) |
|
| age ≥ 60 years | 0.076 | 2.69 (0.90–8.00) |
0.028 | 3.76 (1.15–12.20) |
0.252 | 0.711 | 0.943 | 0.994 | ||||||||||||
| l-ASP | 0.195 | 0.591 | 0.355 | 0.626 | 0.307 | |||||||||||||||
| Female | 0.890 | 0.564 | 0.428 | 0.418 | 0.920 | |||||||||||||||
| stage II | 0.103 | 2.48 (0.83–7.40) |
0.040 | 3.43 (1.05–11.11) |
0.035 | 2.88 (1.08–7.67) |
0.048 | 2.70 (1.01–7.22) |
0.286 | 0.046 | 2.24 (1.01–4.93) |
0.061 | 2.13 (0.96–4.71) |
0.143 | 2.26 (0.76–6.74) |
0.090 | 3.29 (0.83–12.99) |
|||
| B symptoms | 0.255 | 0.409 | 0.187 | 0.655 | 0.105 | 2.52 (0.82–7.73) |
0.030 | 5.12 (1.18–22.36) |
||||||||||||
| EQD2 < 40 Gy | 0.439 | 0.841 | 0.082 | 0.17 (0.02–1.26) |
0.965 | 0.259 | 0.901 | |||||||||||||
| LDHpreCTx > 225 IU/L | 0.189 | 0.249 | 0.745 | 0.623 | 0.379 | |||||||||||||||
| LDHpostCTx > 225 IU/L | 0.726 | 0.938 | 0.068 | 3.14 (0.92–10.75) |
0.205 | 0.205 | 0.141 | 2.59 (0.73–9.17) |
0.630 | 0.68 (0.14–3.28) |
||||||||||
| LDHpostRT>225 IU/L | 0.957 | 0.954 | 0.513 | 0.922 | 0.459 | |||||||||||||||
| CR after CTx | 0.049 | 2.99 (1.00–8.92) |
0.033 | 3.40 (1.10–10.46) |
0.017 | 3.34 (1.24–8.97) |
0.023 | 3.16 (1.17–8.51) |
0.004 | 4.83 (1.65–14.15) |
0.041 | 4.03 (1.06–15.29) |
0.002 | 3.42 (1.55–7.55) |
0.003 | 3.32 (1.51–7.33) |
0.006 | 5.16 (1.59–16.76) |
0.013 | 8.24 (1.57–43.36) |
| Use of IMRT | 0.265 | 0.299 | 0.293 | 0.952 | 0.083 | 0.16 (0.02–1.27) |
0.093 | 0.14 (0.01–1.39) |
||||||||||||
HR, hazard ratio; CI, confidence interval; l-ASP, l-asparaginase-containing chemotherapy, EQD2, equivalent dose in 2 Gy fractions; LDHpreCTx, lactate dehydrogenase before chemotherapy; LDHpostCTx, lactate dehydrogenase after chemotherapy; LDHpostRT, lactate dehydrogenase after radiotherapy; CR, complete response; CTx, chemotherapy; IMRT, intensity-modulated radiation therapy.